Skip to content
Clinical Trials – home
Verifiedinfo

Centre hospitalier universitaire de Liege

Belgium Avenue De L'Hopital 1, 4000 Liege, Belgium

  • 165 trials recruiting
  • Non-small cell lung cancer · Crohn's disease · Breast cancer
  • Adults and children

About Specializations

Centre hospitalier universitaire de Liege in Liege, Belgium specialises in clinical trials of conditions such as Non-small cell lung cancer, Crohn's disease, Breast cancer, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Inflammatory Bowel Disease

The Centre hospitalier universitaire de Liege runs a strong program in digestive system diseases, especially Crohn’s disease and ulcerative colitis. Research here focuses on improving symptom control, mucosal and transmural healing, and long-term disease management with newer treatments and care strategies.

  • Moderate to severe Crohn’s disease and ulcerative colitis
  • Inflammatory bowel disease with postoperative recurrence or fistulizing disease
  • Studies of treatment effectiveness, healing outcomes, and safer disease control

This work reflects a broad effort to improve daily quality of life and reduce relapse in people with chronic intestinal inflammation.

Oncology and Solid Tumor Research

Medical oncology at this site includes extensive research in neoplasms, with a major focus on breast cancer, lung cancer, ovarian cancer, endometrial cancer, colorectal cancer, and gastroesophageal cancers. Many trials aim to test new cancer therapies, compare treatment options, and improve outcomes in advanced or hard-to-treat disease.

  • Breast cancer, including HER2-positive, HER2-low, and hormone receptor-positive disease
  • Non-small cell lung cancer, small cell lung cancer, and head and neck squamous cell carcinoma
  • Ovarian, endometrial, colorectal, pancreatic, and urothelial cancers

The research portfolio is centered on testing targeted and immune-based approaches, as well as evaluating how well established treatments work in different cancer settings.

Hematology, Leukemia, and Lymphoma

This site has a major research presence in hemic and lymphatic diseases, especially acute leukemias, multiple myeloma, myelodysplastic syndromes, and lymphomas. The studies are designed to improve frontline therapy, support remission, and help patients with relapsed or refractory blood cancers.

  • Acute lymphoblastic leukemia and acute myeloid leukemia
  • Follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and related non-Hodgkin lymphomas
  • Multiple myeloma, myelofibrosis, and myelodysplastic syndromes

Several trials also explore hematopoietic stem cell transplantation and immune-based strategies to improve long-term control of hematologic malignancies.

Autoimmune, Rheumatology, and Dermatology Studies

Another important area at Centre hospitalier universitaire de Liege is research in immune system diseases, skin and connective tissue diseases, and inflammatory joint conditions. Trials often aim to ease chronic inflammation, reduce flares, and improve patient-reported symptoms in long-lasting autoimmune disorders.

  • Systemic lupus erythematosus, cutaneous lupus, and lupus nephritis
  • Psoriasis, atopic dermatitis, hidradenitis suppurativa, and vitiligo
  • Rheumatoid arthritis, psoriatic arthritis, and giant cell arteritis

These studies are aimed at better symptom relief, longer disease control, and more personalized treatment choices for people with chronic immune-mediated conditions.

Pulmonary, Kidney, and Cardiometabolic Research

The site also studies respiratory tract diseases, kidney diseases, and cardiovascular and metabolic disorders. Research includes chronic lung inflammation, fibrotic lung disease, kidney function preservation, and conditions linked to obesity, diabetes, and hypertension.

  • Asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and progressive pulmonary fibrosis
  • IgA nephropathy, chronic kidney disease, focal segmental glomerulosclerosis, and primary hyperoxaluria
  • Obesity, type 2 diabetes, resistant hypertension, and atherosclerotic cardiovascular disease

Trials in this area are generally focused on improving long-term disease control, protecting organ function, and reducing complications.

Infectious Disease, Transplantation, and Critical Care

Research at this hospital also covers virus diseases, bacterial infections, and complex care in transplant and intensive care settings. The studies address prevention, treatment effectiveness, and recovery in patients with serious infections or immune suppression.

  • COVID-19, cytomegalovirus, Epstein-Barr virus, and herpes zoster
  • Acute graft-versus-host disease and chronic graft-versus-host disease
  • Sepsis, severe community-acquired pneumonia, and other critical infections

These trials are intended to improve infection control, support transplant outcomes, and strengthen care for vulnerable patients in hospital-based settings.

Neurology, Ophthalmology, and Other Specialized Fields

The research portfolio further includes nervous system diseases, eye diseases, and selected procedural and supportive care studies. This broad activity shows the site’s interest in both disease-specific therapies and practical improvements in patient care.

  • Multiple sclerosis, Parkinson’s disease, stroke, and disorders of consciousness
  • Thyroid eye disease and glaucoma
  • Anesthesia, surgical procedures, and other diagnostic or therapeutic techniques

Across these topics, the emphasis is on evaluating effectiveness, improving function, and supporting better outcomes in specialized clinical care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenue De L'Hopital 14000 LiegeBelgium
Recruiting now
165 trials
Conditions studied
174
Partner status
Verified

More sites in LiegeBelgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

417 clinical trials

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).